{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:15:05Z","timestamp":1778807705887,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Alendronate is an antiresorptive therapy for osteoporosis and results in a decrease in bone turnover. To choose the optimal measurement for monitoring this therapy, the size of the change needs to be compared with the variability of the measurement. We studied 26 women with postmenopausal osteoporosis (bone mineral density [BMD] T score &amp;lt; \u20132.5), who were randomized in a 2:1 ratio to receive alendronate (10 mg\/day) and calcium carbonate (500 mg\/day) or calcium carbonate alone for 6 months. We measured serum markers of bone formation (osteocalcin [OC], bone isoform of alkaline phosphatase [BAP], and collagen type I C-terminal propeptide [CICP]) and urinary markers of bone resorption (cross-linked N-telopeptide [NTx], free deoxypyridinoline [iFDpd], and free pyridinolines). All subjects had two measurements 1 week apart at baseline to calculate the short-term variability. Biochemical measurements were then made at 4, 8, 12, 24, and 25 weeks. Measurements of bone mass were made by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and proximal femur twice at baseline and then at 24 and 25 weeks. The mean difference in change in BMD and markers between both groups at the end of the study that were significant were (short-term variability in brackets): DXA total hip 4.3% (2.5%), NTX 49% (10%), iFDpd 22% (12%), OC 28% (13%), BAP 31% (13%), and CICP 31% (11%). Five of the six markers showed significant responses to alendronate therapy, but they differed in the relationship between size of response and variability. These biochemical markers performed better than DXA for monitoring alendronate therapy over 6 months.<\/jats:p>","DOI":"10.1359\/jbmr.1999.14.4.602","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T01:11:44Z","timestamp":1146100304000},"page":"602-608","source":"Crossref","is-referenced-by-count":62,"title":["Monitoring Alendronate Therapy for Osteoporosis"],"prefix":"10.1093","volume":"14","author":[{"given":"Adriana Braga","family":"De castro machado","sequence":"first","affiliation":[{"name":"Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Hannon","sequence":"additional","affiliation":[{"name":"Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Prof. Eastell","sequence":"additional","affiliation":[{"name":"Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020713381864300_bib1","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garner","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713381864300_bib2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1359\/jbmr.1997.12.3.472","article-title":"Androgen supplementation in eugonadal men with osteoporosis: Effects of six months treatment on markers of bone formation and resorption","volume":"12","author":"Anderson","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020713381864300_bib3","first-page":"1904","article-title":"The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement therapy or calcium supplementation","volume":"82","author":"Rosen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713381864300_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024020713381864300_bib5","first-page":"730","article-title":"The effect of calcium supplementation on the circadian rhythm of bone resorption","volume":"79","author":"Blumsohn","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713381864300_bib6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/000456329002700607","article-title":"The reproducibility of bone related biochemical variables in postmenopausal women","volume":"27","author":"Morris","year":"1990","journal-title":"Ann Clin Biochem"},{"key":"2024020713381864300_bib7","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/clinchem\/41.11.1592","article-title":"Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease","volume":"41","author":"Blumsohn","year":"1995","journal-title":"Clin Chem"},{"key":"2024020713381864300_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jbmr.5650100418","article-title":"Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-link excretion","volume":"10","author":"Garnero","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024020713381864300_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodelling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2024020713381864300_bib10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbmr.5650091121","article-title":"Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis","volume":"9","author":"Rossini","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713381864300_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S8756-3282(97)00105-1","article-title":"Osteoclasts generate crosslinked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone","volume":"21","author":"Apone","year":"1997","journal-title":"Bone"},{"key":"2024020713381864300_bib12","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/jbmr.5650111220","article-title":"The renal clearance of free and conjugated pyridinium cross-links of collagen","volume":"11","author":"Colwell","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020713381864300_bib13","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jbmr.5650110817","article-title":"Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationship between measurements of the different forms of pyridinoline cross-links","volume":"11","author":"Randall","year":"1996","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2024020713381864300_bib14","first-page":"S143","article-title":"Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides","volume":"7","author":"Eyre","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020713381864300_bib15","first-page":"3366","article-title":"Bone turnover markers and bone density across the menopausal transition","volume":"81","author":"Ebeling","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713381864300_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jcem-67-4-741","article-title":"Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics and biochemical markers","volume":"67","author":"Eastell","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713381864300_bib17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/jcem-66-5-951","article-title":"Concurrent assays of circulating bone gla-protein and bone alkaline phosphatase: Effects of sex, age and metabolic bone disease","volume":"66","author":"Duda","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713381864300_bib18","first-page":"1046","article-title":"Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease","volume":"77","author":"Garnero","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713381864300_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1359\/jbmr.1997.12.1.124","article-title":"Sources of variability in bone mineral density measurements: Implications for study design and analysis of bone loss","volume":"12","author":"Nguyen","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020713381864300_bib20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/jbmr.5650100704","article-title":"Reproducibility of DXA absorptiometry: A model for bone loss estimates","volume":"10","author":"Fuleihan","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024020713381864300_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02556113","article-title":"Precision and stability of dual-energy x-ray absorptiometry measurements","volume":"49","author":"Johnson","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2024020713381864300_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1259\/0007-1285-65-771-213","article-title":"Bone mineral density in healthy normal women and reproducibility of measurements in spine and hip using dual-energy absorptiometry","volume":"65","author":"Haddaway","year":"1992","journal-title":"Br J Radiol"},{"key":"2024020713381864300_bib23","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/clinchem\/43.9.1570","article-title":"Comparison of analytical performance and biological variability of three bone resorption assays","volume":"43","author":"Ju","year":"1997","journal-title":"Clin Chem"},{"key":"2024020713381864300_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF02352259","article-title":"Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: Do they exist?","volume":"4","author":"Hassager","year":"1994","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1999.14.4.602","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/4\/602\/56599266\/5650140416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/4\/602\/56599266\/5650140416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:58:03Z","timestamp":1710341883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/14\/4\/602-608\/7514875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4,1]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[1999,4,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1999.14.4.602","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,4,1]]},"published":{"date-parts":[[1999,4,1]]}}}